全文获取类型
收费全文 | 1682739篇 |
免费 | 126416篇 |
国内免费 | 3751篇 |
专业分类
耳鼻咽喉 | 21710篇 |
儿科学 | 55487篇 |
妇产科学 | 46140篇 |
基础医学 | 239547篇 |
口腔科学 | 48685篇 |
临床医学 | 150236篇 |
内科学 | 330709篇 |
皮肤病学 | 38626篇 |
神经病学 | 130283篇 |
特种医学 | 63796篇 |
外国民族医学 | 242篇 |
外科学 | 256465篇 |
综合类 | 38817篇 |
现状与发展 | 4篇 |
一般理论 | 531篇 |
预防医学 | 123348篇 |
眼科学 | 40007篇 |
药学 | 123231篇 |
7篇 | |
中国医学 | 4345篇 |
肿瘤学 | 100690篇 |
出版年
2019年 | 13519篇 |
2018年 | 19949篇 |
2017年 | 15212篇 |
2016年 | 16611篇 |
2015年 | 18957篇 |
2014年 | 26212篇 |
2013年 | 37940篇 |
2012年 | 52724篇 |
2011年 | 55413篇 |
2010年 | 32766篇 |
2009年 | 30691篇 |
2008年 | 51515篇 |
2007年 | 54793篇 |
2006年 | 55252篇 |
2005年 | 52535篇 |
2004年 | 50737篇 |
2003年 | 48071篇 |
2002年 | 46239篇 |
2001年 | 91685篇 |
2000年 | 93437篇 |
1999年 | 76600篇 |
1998年 | 18774篇 |
1997年 | 16266篇 |
1996年 | 16418篇 |
1995年 | 16636篇 |
1994年 | 15228篇 |
1993年 | 14000篇 |
1992年 | 57307篇 |
1991年 | 55258篇 |
1990年 | 52945篇 |
1989年 | 50724篇 |
1988年 | 46108篇 |
1987年 | 44920篇 |
1986年 | 42194篇 |
1985年 | 39978篇 |
1984年 | 29311篇 |
1983年 | 24844篇 |
1982年 | 13842篇 |
1981年 | 12325篇 |
1979年 | 25467篇 |
1978年 | 17528篇 |
1977年 | 14849篇 |
1976年 | 13829篇 |
1975年 | 14513篇 |
1974年 | 17601篇 |
1973年 | 16907篇 |
1972年 | 15664篇 |
1971年 | 14433篇 |
1970年 | 13415篇 |
1969年 | 12504篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
82.
Michael T Milano Veronica L S Chiang Scott G Soltys Tony J C Wang Simon S Lo Alexandria Brackett Seema Nagpal Samuel Chao Amit K Garg Siavash Jabbari Lia M Halasz Melanie Hayden Gephart Jonathan P S Knisely Arjun Sahgal Eric L Chang 《Neuro-oncology》2020,22(12):1728
BackgroundThe American Radium Society (ARS) Appropriate Use Criteria brain malignancies panel systematically reviewed (PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses]) published literature on neurocognitive outcomes after stereotactic radiosurgery (SRS) for patients with multiple brain metastases (BM) to generate consensus guidelines.MethodsThe panel developed 4 key questions (KQs) to guide systematic review. From 11 614 original articles, 12 were selected. The panel developed model cases addressing KQs and potentially controversial scenarios not addressed in the systematic review (which might inform future ARS projects). Based upon quality of evidence, the panel confidentially voted on treatment options using a 9-point scale of appropriateness.ResultsThe panel agreed that SRS alone is usually appropriate for those with good performance status and 2–10 asymptomatic BM, and usually not appropriate for >20 BM. For 11–15 and 16–20 BM there was (between 2 case variants) agreement that SRS alone may be appropriate or disagreement on the appropriateness of SRS alone. There was no scenario (among 6 case variants) in which conventional whole-brain radiotherapy (WBRT) was considered usually appropriate by most panelists. There were several areas of disagreement, including: hippocampal sparing WBRT for 2–4 asymptomatic BM; WBRT for resected BM amenable to SRS; fractionated versus single-fraction SRS for resected BM, larger targets, and/or brainstem metastases; optimal treatment (WBRT, hippocampal sparing WBRT, SRS alone to all or select lesions) for patients with progressive extracranial disease, poor performance status, and no systemic options.ConclusionsFor patients with 2–10 BM, SRS alone is an appropriate treatment option for well-selected patients with good performance status. Future study is needed for those scenarios in which there was disagreement among panelists. 相似文献
83.
84.
Schaff Lauren R. Yan Dongyao Thyparambil Sheeno Tian Yuan Cecchi Fabiola Rosenblum Marc Reiner Anne S. Panageas Katherine S. Hembrough Todd Lin Andrew L. 《Journal of neuro-oncology》2020,146(1):163-170
Journal of Neuro-Oncology - Understanding the molecular landscape of glioblastoma (GBM) is increasingly important in the age of targeted therapy. O-6-Methylguanine-DNA methyltransferase (MGMT)... 相似文献
85.
Dengue, a mosquito‐borne viral disease, causes about 100 million cases of infection annually. It is a major public concern, and if left untreated or improperly diagnosed, may cause serious health problems or even death. Historically, dengue has not considered priorities for pharmaceutical companies made the available treatment options. Therefore, medicinal scientists are revealing new insights and enabling novel interventions and approaches to dengue prevention and control. Diterpenes, a class of terpenes have gained much attention due to their diverse biological effects. This review aimed at summarizing available evidences of diterpenes and their derivatives acting against dengue virus and their vectors. For this, an updated search was made in the databases: PubMed and ScienceDirect by using specific keywords. Among the 117 published reports, a total of 30 articles was included in this review. Findings suggest that a number of diterpenes and/or their derivatives act against dengue virus and their two potential vectors namely Aedes aegypti and Ae. albopictus. In conclusion, diterpenes and their derivatives may have the potential alternative therapeutic tools for the management of dengue virus and some associated diseases transmitted by Aedes mosquito. 相似文献
86.
87.
Implications for Practice
Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.88.
89.
M.S. Iqbal G. Vashisht R. McMenemin P. Atherton F. McDonald T. Simmons A. Bradshaw J. Kovarik H. Turnbull L. Dodd P. Mulvenna A. Greystoke 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):e1-e10
Aims
Concomitant chemoradiation is the standard of care in patients with inoperable non-small cell lung cancer. The purpose of this study was to analyse the survival outcome and toxicity data of using hypofractionated chemoradiation.Materials and methods
One hundred patients were treated from June 2011 to November 2016. Treatment consisted of 55 Gy in 20 daily fractions concurrently with split-dose cisplatin vinorelbine chemotherapy over 4 weeks followed by two cycles of cisplatin vinorelbine only. Survival was estimated using Kaplan–Meier and Cox regression was carried out for known prognostic factors. A systematic search of literature was conducted using Medline, Embase and Cochrane databases and relevant references included.Results
In total, 97% of patients completed radiotherapy and 73% of patients completed all four cycles of chemotherapy. One patient died of a cardiac event during consolidative chemotherapy. There were two cases of grade 4 toxicities (one sepsis, one renal impairment). Grade 3 toxicities included nausea/vomiting (17%), oesophagitis (15%), infection with neutropenia (12%) and pneumonitis (4%). Clinical benefit was seen in 86%. Two-year progression-free survival and overall survival rates were 49% and 58%, respectively. The median progression-free survival and overall survival were 23.4 and 43.4 months, respectively. The only significant prognostic factor was the number of chemotherapy cycles received (P = 0.02). The systematic review identified 13 relevant studies; a variety of regimens were assessed with variable reporting of outcomes and toxicity but with overall an improvement in survival over time.Conclusion
Our experience compared with the original phase II trial showed improved treatment completion rates and survival with acceptable morbidity. With appropriate patient selection this regimen is an effective treatment option for locally advanced non-small cell lung cancer. This study helps to benchmark efficacy and toxicity rates while considering the addition of new agents to hypofractionated concurrent chemoradiotherapy. The agreement of a standard regimen for assessment in future trials would be beneficial. 相似文献90.